RETHAM TECHNOLOGIES, INC.
WAUWATOSA, WI · CIK 0002144681 · Medtech · Private
HITDx, a functional in vitro diagnostic (IVD) assay using cryopreserved platelets to detect pathogenic antibodies in heparin-induced thrombocytopenia (HIT)
- Grants
- $4.8M
- 6 awards
- Sector median: 1
- Raised
- $1.1M
- 1 Form D · Sep 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 1 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced Thrombocytopenia | $224,671 | |
| Federal grant | Department of Health and Human Services · Phase II · An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced Thrombocytopenia | $479,730 | |
| Federal grant | Department of Health and Human Services · Phase II · An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced Thrombocytopenia | $1,220,267 | |
| Federal grant | Department of Health and Human Services · Phase II · An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-induced Thrombocytopenia | $49,399 | |
| Federal grant | Department of Health and Human Services · Phase II · An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia | $1,154,002 | |
| Federal grant | Department of Health and Human Services · Phase II · An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia | $1,693,897 | |
| Private capital raised | Form D · SEC | $1,060,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1593 | 4C Medical Technologies, Inc. | — | $136M |
| 1594 | Beacon Power Services, Corp. | — | $30M |
| 1595 | Cape Bioresearch, Inc. | — | — |
| 1596 | RETHAM TECHNOLOGIES, INC. | — | $1.1M |
| 1597 | INTUS BIOSCIENCES LLC | — | $8.8M |
| 1598 | FirstVitals Inc. | — | $250K |
| 1599 | DIADEM US, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Identification Of Platelet Activating Antibodiesgranted
- Polyvinyl Sulfonate-treated Platelets For The Detection Of Antiplatelet Factor 4 Antibodiesapplication
- Polyvinyl Sulfonate-treated Platelets For The Detection Of Anti-platelet Factor 4 Antibodiesapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.